VYNE Therapeutics (VYNE) Operating Margin (2017 - 2026)

VYNE Therapeutics (VYNE) operating margin from Jun 30, 2017 to Mar 31, 2026. The current VYNE Therapeutics (VYNE) operating margin is -4244.44%. You can export chart.

All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.

Annual Operating Margin

Quarterly Operating Margin

Annual Operating Margin change of VYNE Therapeutics (VYNE)

Year	Operating Margin	Change
2025	-5219.30%	-40.20%
2024	-8728.00%	+25.28%
2023	-6966.67%	-2.48%
2022	-7143.75%	+70.74%
2021	-4183.87%	+247.73%
2020	-1203.19%	N/A
2020	0.00%	N/A
2020	0.00%	N/A
2020	0.00%	-100.00%
2019	-21788.64%	+325.34%
2019	-5122.58%	+146.25%
2018	-2080.28%	N/A
2018	0.00%	N/A
2018	0.00%	-100.00%
2017	-646.07%	N/A
2017	0.00%	N/A
2017	0.00%	N/A
2017	0.00%	-100.00%
2016	-2138.81%	N/A

Comparison VYNE Therapeutics (VYNE) operating margin with competitors

VYNE Therapeutics (VYNE) operating margin is -4244.44%.

Ticker	Name	Operating Margin	Upside
VIR	Vir Biotechnology Inc	459241.00%	-10919.81%
APLM	Apollomics Inc - Class A	431.90%	-110.18%
ABUS	Arbutus Biopharma Corp	94.30%	-102.22%
SAVA	Cassava Sciences Inc.	93.36%	-102.20%
RPRX	Royalty Pharma plc - Class A	89.29%	-102.10%
GLPG	Galapagos NV	84.24%	-101.98%
NEUP	Neuphoria Therapeutics Inc	79.85%	-101.88%
BDTX	Black Diamond Therapeutics Inc	77.90%	-101.84%
CTNM	Contineum Therapeutics Inc - Class A	77.87%	-101.83%
CVAC	CureVac N.V.	74.59%	-101.76%
IPSC	Century Therapeutics Inc	67.95%	-101.60%
FULC	Fulcrum Therapeutics Inc	65.62%	-101.55%
AVIR	Atea Pharmaceuticals Inc	63.06%	-101.49%
PLX	Protalix BioTherapeutics Inc	62.65%	-101.48%
PRTA	Prothena Corporation plc	58.80%	-101.39%
AUPH	Aurinia Pharmaceuticals Inc	53.31%	-101.26%
ADMA	Adma Biologics Inc	50.90%	-101.20%
RPTX	Repare Therapeutics Inc	50.85%	-101.20%
CRMD	CorMedix Inc	49.96%	-101.18%
HCWB	HCW Biologics Inc	49.45%	-101.17%
CPRX	Catalyst Pharmaceuticals Inc	49.02%	-101.15%
SRPT	Sarepta Therapeutics Inc	49.00%	-101.15%
HALO	Halozyme Therapeutics Inc	48.98%	-101.15%
KRYS	Krystal Biotech Inc	46.14%	-101.09%
AGEN	Agenus Inc	44.62%	-101.05%
CGEN	Compugen Ltd	43.05%	-101.01%
SVA	Sinovac Biotech Ltd	42.30%	-101.00%
EXEL	Exelixis Inc	41.15%	-100.97%
QTTB	Q32 Bio Inc	39.80%	-100.94%
INVA	Innoviva Inc	38.94%	-100.92%
VRTX	Vertex Pharmaceuticals Inc	38.10%	-100.90%
NXTC	Nextcure Inc	36.70%	-100.86%
LGND	Ligand Pharmaceuticals Inc - Class B	33.58%	-100.79%
SLNO	Soleno Therapeutics Inc	33.06%	-100.78%
JAZZ	Jazz Pharmaceuticals plc	31.49%	-100.74%
ARGX	Argen X SE	30.35%	-100.72%
CAI	Caris Life Sciences Inc - Class A	30.19%	-100.71%
TNGX	Tango Therapeutics Inc	26.15%	-100.62%
GMAB	Genmab	25.11%	-100.59%
ZVRA	Zevra Therapeutics Inc	24.40%	-100.57%
TECH	Bio-Techne Corp	24.24%	-100.57%
INCY	Incyte Corp	23.66%	-100.56%
RIGL	Rigel Pharmaceuticals	20.21%	-100.48%
ICCC	Immucell Corp	19.01%	-100.45%
REGN	Regeneron Pharmaceuticals Inc	17.83%	-100.42%
NERV	Minerva Neurosciences Inc	17.73%	-100.42%
HRMY	Harmony Biosciences Holdings Inc	17.31%	-100.41%
TGTX	TG Therapeutics Inc	16.98%	-100.40%
BMRN	Biomarin Pharmaceutical Inc	16.92%	-100.40%
ONC	BeiGene Ltd	16.51%	-100.39%
PTCT	PTC Therapeutics Inc	16.50%	-100.39%
PHAR	Pharming Group N.V.	16.26%	-100.38%
ENVB	Enveric Biosciences Inc	13.38%	-100.32%
VRNA	Verona Pharma Plc	12.90%	-100.30%
ALNY	Alnylam Pharmaceuticals Inc	12.01%	-100.28%
ASND	Ascendis Pharma A/S	10.06%	-100.24%
APLS	Apellis Pharmaceuticals Inc	9.86%	-100.23%
FOLD	Amicus Therapeutics Inc	8.61%	-100.20%
CGEM	Cullinan Oncology Inc	7.24%	-100.17%
IMCR	Immunocore Holdings plc	6.82%	-100.16%
NAGE	Niagen Bioscience Inc	5.01%	-100.12%
NUVB	Nuvation Bio Inc - Class A	4.66%	-100.11%
BMEA	Biomea Fusion Inc	2.46%	-100.06%
TLX	Telix Pharmaceuticals Ltd	1.58%	-100.04%
HOTH	Hoth Therapeutics Inc	0.17%	-100.00%
BBLG	Bone Biologics Corp	0.04%	-100.00%